Cytokinetics Statistics
Total Valuation
Cytokinetics has a market cap or net worth of $6.29 billion. The enterprise value is $6.42 billion.
| Market Cap | 6.29B |
| Enterprise Value | 6.42B |
Important Dates
The next estimated earnings date is Thursday, August 1, 2024, after market close.
| Earnings Date | Aug 1, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytokinetics has 114.66 million shares outstanding. The number of shares has increased by 7.10% in one year.
| Shares Outstanding | 114.66M |
| Shares Change (YoY) | +7.10% |
| Shares Change (QoQ) | +2.85% |
| Owned by Insiders (%) | 0.50% |
| Owned by Institutions (%) | 103.99% |
| Float | 104.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,675.86 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,712.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.19
| Current Ratio | 7.19 |
| Quick Ratio | 6.98 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.65 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -67.30% |
| Return on Capital (ROIC) | -138.80% |
| Revenue Per Employee | $8,870 |
| Profits Per Employee | -$1.25M |
| Employee Count | 423 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +64.39% in the last 52 weeks. The beta is 0.75, so Cytokinetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.75 |
| 52-Week Price Change | +64.39% |
| 50-Day Moving Average | 56.95 |
| 200-Day Moving Average | 56.28 |
| Relative Strength Index (RSI) | 51.89 |
| Average Volume (20 Days) | 2,300,138 |
Short Selling Information
The latest short interest is 16.04 million, so 13.99% of the outstanding shares have been sold short.
| Short Interest | 16.04M |
| Short Previous Month | 16.42M |
| Short % of Shares Out | 13.99% |
| Short % of Float | 15.38% |
| Short Ratio (days to cover) | 5.67 |
Income Statement
In the last 12 months, Cytokinetics had revenue of $3.75 million and -$530.60 million in losses. Loss per share was -$5.40.
| Revenue | 3.75M |
| Gross Profit | 3.75M |
| Operating Income | -497.97M |
| Pretax Income | -530.60M |
| Net Income | -530.60M |
| EBITDA | -489.78M |
| EBIT | -502.15M |
| Loss Per Share | -$5.40 |
Balance Sheet
The company has $618.96 million in cash and $754.92 million in debt, giving a net cash position of -$135.96 million or -$1.19 per share.
| Cash & Cash Equivalents | 618.96M |
| Total Debt | 754.92M |
| Net Cash | -135.96M |
| Net Cash Per Share | -$1.19 |
| Equity (Book Value) | -396.16M |
| Book Value Per Share | -3.46 |
| Working Capital | 549.85M |
Cash Flow
In the last 12 months, operating cash flow was -$421.55 million and capital expenditures -$1.01 million, giving a free cash flow of -$422.57 million.
| Operating Cash Flow | -421.55M |
| Capital Expenditures | -1.01M |
| Free Cash Flow | -422.57M |
| FCF Per Share | -$4.15 |
Margins
Gross margin is 100.00%, with operating and profit margins of -13,272.04% and -14,141.74%.
| Gross Margin | 100.00% |
| Operating Margin | -13,272.04% |
| Pretax Margin | -14,141.74% |
| Profit Margin | -14,141.74% |
| EBITDA Margin | -13,053.70% |
| EBIT Margin | -13,383.53% |
| FCF Margin | -11,262.47% |
Dividends & Yields
Cytokinetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.10% |
| Shareholder Yield | -7.10% |
| Earnings Yield | -8.44% |
| FCF Yield | -6.72% |
Analyst Forecast
The average price target for Cytokinetics is $78.25, which is 42.69% higher than the current price. The consensus rating is "Buy".
| Price Target | $78.25 |
| Price Target Difference | 42.69% |
| Analyst Consensus | Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (5Y) | 193.39% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on June 25, 2013. It was a reverse split with a ratio of 1:6.
| Last Split Date | Jun 25, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:6 |
Scores
Cytokinetics has an Altman Z-Score of -1.99 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.99 |
| Piotroski F-Score | 2 |